Top

Radiation Oncology

Published in:

Open Access 01-12-2017 | Research

Predictive factors of acute skin reactions to carbon ion radiotherapy for the treatment of malignant bone and soft tissue tumors

Authors: Yosuke Takakusagi, Jun-ichi Saitoh, Hiroki Kiyohara, Takahiro Oike, Shin-ei Noda, Tatsuya Ohno, Takashi Nakano

Published in: Radiation Oncology | Issue 1/2017

Abstract

Background

The skin is considered a critical organ at risk in carbon ion radiotherapy (CIRT) for locally advanced malignant bone and soft tissue tumors (MBSTs). The predictive factors for acute skin reactions after CIRT have not been investigated. The present study aimed to identify these factors and evaluate the correlation between the severity of acute skin reactions and skin dose parameters.

Methods

CIRT with total doses of 64.0–70.4 Gy (relative biological effectiveness [RBE]) was administered to 22 patients with MBSTs. The skin-tumor distance (STD), maximum skin total dose (Dmax), and area of the skin receiving a total dose of X Gy (RBE) were evaluated.

Results

All patients developed acute skin reactions after CIRT, including Grades 1 and 2 dermatitis in 15 (71%) and 6 (29%) patients, respectively. There was a significant difference in the STD between the two groups (P = 0.007), and the cut-off value of STD for predicting Grade 2 acute skin reactions was 11 mm. There was a significant difference in Dmax between the groups (P < 0.001), and the cut-off value of Dmax for predicting Grade 2 acute skin reactions was 52 Gy (RBE). Significant differences between the two groups were observed in terms of the area irradiated with 40 Gy (RBE) (S40), and the cut-off value of S40 for predicting Grade 2 acute skin reactions was 25 cm².

Conclusions

In acute skin reactions after CIRT for MBSTs, STD, Dmax, and S40 were found to be significant predictive factors for acute skin reactions.

Von Burton G, Rankin C, Zalupski MM, Mills GM, Borden EC, Karen A. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am J Clin Oncol. 2006;29:59–61.CrossRefPubMed

Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824–31.CrossRefPubMed

Basaran M, Bavbek ES, Saglam S, Eralp L, Sakar B, Atalar AC, Bilgic B, Ozger H, Onat H. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. Oncology. 2007;72:255–60.CrossRefPubMed

Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma intergroup. J Natl Cancer Inst. 2007;99:112–28.CrossRefPubMed

DeLaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, Rosenberg AL, Rosenthal DI, Miryousefi F, Ancukiewicz M, Harmon DC. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003;56:1117–27.CrossRefPubMed

Grimer RJ, Carter SR, Tillman RM, Spooner D, Mangham DC, Kabukcuoglu Y. Osteosarcoma of the pelvis. J Bone Joint Surg. 1999;81:796–802.CrossRef

Duffaud F, Digue L, Baciuchka-Palmaro M, Volot F, Perles-Daniel C, Garbe L, Favre R. Osteosarcoma of flat bones in adolescents and adults. Cancer. 2000;88:324–32.CrossRefPubMed

Ozaki T, Flege S, Kevric M, Lindner N, Maas R, Delling G, Schwarz R, von Hochstetter AR, Salzer-Kuntschik M, Berdel WE, Jürgens H, Exner GU, Reichardt P, Mayer-Steinacker R, Ewerbeck V, Kotz R, Winkelmann W, Bielack SS. Osteosarcoma of the pelvis: experience of the cooperative Osteosarcoma study group. J Clin Oncol. 2003;21:334–41.CrossRefPubMed

Cheng EY, Ozerdemoglu RA, Transfeldt EE, Thompson RC Jr. Lumbosacral chordoma. Prognostic factors and treatment. Spine. 1999;24:1639–45.CrossRefPubMed

10.

Tepper JE, Suit HD. Radiation therapy alone for sarcoma of soft tissue. Cancer. 1985;56:475–9.CrossRefPubMed

11.

Machak GN, Tkachev SI, Solovyev YN, Sinyukov PA, Ivanov SM, Kochergina NV, Ryjkov AD, Tepliakov VV, Bokhian BY, Glebovskaya VV. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc. 2003;78:147–55.CrossRefPubMed

12.

Kanai T, Endo M, Minohara S, Miyahara N, Koyama-ito H, Tomura H, Matsufuji N, Futami Y, Fukumura A, Hiraoka T, Furusawa Y, Ando K, Suzuki M, Soga F, Kawachi K. Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44:201–10.CrossRefPubMed

13.

Kanai T, Matsufuji N, Miyamoto T, Mizoe J, Kamada T, Tsuji H, Kato H, Baba M, Tsujii H. Examination of GyE system for HIMAC carbon therapy. Int J Radiat Oncol Biol Phys. 2006;64:650–6.CrossRefPubMed

14.

Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25:953–64.CrossRefPubMed

15.

Kamada T, Tsujii H, Tsuji H, Yanagi T, Mizoe JE, Miyamoto T, Kato H, Yamada S, Morita S, Yoshikawa K, Kandatsu S, Tateishi A. Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol. 2002;20:4466–71.CrossRefPubMed

16.

Imai R, Kamada T, Araki N. Carbon ion radiation therapy for Unresectable sacral Chordoma: an analysis of 188. Int J Radiat Oncol Biol Phys. 2016;95:322–7.CrossRefPubMed

17.

Matsunobu A, Imai R, Kamada T, Imaizumi T, Tsuji H, Tsujii H, Shioyama Y, Honda H, Tatezaki S. Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer. 2012;118:4555–63.CrossRefPubMed

18.

Lee N, Chuang C, Quivey JM, Phillips TL, Akazawa P, Verhey LJ, Xia P. Skin toxicity due to intensity-modulated radiotherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys. 2002;53:630–7.CrossRefPubMed

19.

Yanagi T, Kamada T, Tsuji H, Imai R, Serizawa I, Tsujii H. Dose-volume histogram and dose-surface histogram analysis for skin reactions to carbon ion radiotherapy for bone and soft tissue sarcoma. Radiother Oncol. 2010;95:60–5.CrossRefPubMed

20.

Hopewell JW. The skin: its structure and response to ionizing radiation. Int J Radiat Biol. 1990;57:751–73.CrossRefPubMed

21.

Shimizu H. Shimizu’s textbook of dermatology. Hokkaido: Hokkaido University Press/Nakayama Shoten; 2007.

22.

Abe T, Tamaki T, Makino S, Ebara T, Hirai R, Miyaura K, Kumazaki Y, Ohno T, Shikama N, Nakano T, Kato S. Assessing cumulative dose distributions in combined radiotherapy for cervical cancer using deformable image registration with pre-imaging preparations. Radiat Oncol. 2014;9:293.CrossRefPubMedPubMedCentral

23.

Lienger L, Michaud N. Skin and subcutaneous reactions induced by supervoltage irradiation. Am J Roentgenol Radium Therapy, Nucl Med. 1961;85:533–49.

24.

Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22.CrossRefPubMed

25.

Sun LM, Huang EY, Liang JA, Meng FY, Chang GH, Tsao MJ. Evaluation the consistency of location of moist desquamation and skin high dose area for breast cancer patients receiving adjuvant radiotherapy after breast conservative surgery. Radiat Oncol. 2013;8:50.CrossRefPubMedPubMedCentral

26.

Hoppe BS, Laser B, Kowalski AV, Fontenla SC, Pena-Greenberg E, Yorke ED, Lovelock DM, Hunt MA, Rosenzweig KE. Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk? Int J Radiat Oncol Biol Phys. 2008;72(5):1283–6.CrossRefPubMed

27.

Galland-Girodet S, Pashtan I, MacDonald SM, Ancukiewicz M, Hirsch AE, Kachnic LA, Specht M, Gadd M, Smith BL, Powell SN, Recht A, Taghian AG. Long-term cosmetic outcomes and toxicities of proton beam therapy compared with photon-based 3-dimensional conformal accelerated partial-breast irradiation: a phase 1 trial. Int J Radiat Oncol Biol Phys. 2014;90(3):493–500.CrossRefPubMed

Title: Predictive factors of acute skin reactions to carbon ion radiotherapy for the treatment of malignant bone and soft tissue tumors
Authors: Yosuke Takakusagi
Jun-ichi Saitoh
Hiroki Kiyohara
Takahiro Oike
Shin-ei Noda
Tatsuya Ohno
Takashi Nakano
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2017
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/s13014-017-0927-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Predictive factors of acute skin reactions to carbon ion radiotherapy for the treatment of malignant bone and soft tissue tumors

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2017

Down-regulation of LncRNA TUG1 enhances radiosensitivity in bladder cancer via suppressing HMGB1 expression

Finer leaf resolution and steeper beam edges using a virtual isocentre in concurrence to PTV-shaped collimators in standard distance – a planning study

Clinical outcomes of graves’ ophthalmopathy treated with intensity modulated radiation therapy

Difference in the relative biological effectiveness and DNA damage repair processes in response to proton beam therapy according to the positions of the spread out Bragg peak

Radiotherapy plus temozolomide in elderly patients with glioblastoma: a “real-life” report

An integrated strategy of biological and physical constraints in biological optimization for cervical carcinoma